Cargando…
In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma
Multiple myeloma is a life-threatening hematological malignancy, which is rarely curable by conventional therapies. Immunotherapy, using tumor antigen-specific, cytotoxic T-lymphocytes, may represent an alternative or additional treatment for multiple myeloma. In this study, we used hybrid cell line...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687956/ https://www.ncbi.nlm.nih.gov/pubmed/31428094 http://dx.doi.org/10.3389/fimmu.2019.01792 |
_version_ | 1783442811399438336 |
---|---|
author | Khalaf, Wafaa S. Garg, Mamta Mohamed, Yehia S. Stover, Cordula M. Browning, Michael J. |
author_facet | Khalaf, Wafaa S. Garg, Mamta Mohamed, Yehia S. Stover, Cordula M. Browning, Michael J. |
author_sort | Khalaf, Wafaa S. |
collection | PubMed |
description | Multiple myeloma is a life-threatening hematological malignancy, which is rarely curable by conventional therapies. Immunotherapy, using tumor antigen-specific, cytotoxic T-lymphocytes, may represent an alternative or additional treatment for multiple myeloma. In this study, we used hybrid cell lines, generated by fusion of an EBV B-lymphoblastoid cell line (B-LCL) and myeloma cells, to stimulate in vitro peripheral blood lymphocytes (PBLs) from patients with multiple myeloma. We investigated induction of antigen-specific, cytotoxic T-lymphocytes to the well-defined tumor associated antigens (TAAs) hTERT, MUC1, MAGE-C1 and CS1, which have been shown to be expressed in a high proportion of cases of multiple myeloma. HLA-A2-peptide pentamer staining, interferon-γ and perforin ELISpot assays, as well as cytotoxicity assays were used. Following several rounds of in vitro stimulation, the hybrid cell lines induced antigen-specific, cytotoxic T-lymphocytes to four candidate TAAs in PBLs from HLA-A2(+) multiple myeloma patients, using known HLA-A2 restricted peptide epitopes of the TAAs. In contrast, the HLA-A2(+) myeloma cell line U266 failed to induce antigen-specific, cytotoxic T-lymphocytes in vitro. Our data indicate that B-LCL/myeloma hybrid cell lines induce antigen-specific, cytotoxic T-lymphocytes in PBLs isolated from multiple myeloma patients in vitro and may represent a novel strategy for use in adoptive immunotherapy of multiple myeloma. |
format | Online Article Text |
id | pubmed-6687956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66879562019-08-19 In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma Khalaf, Wafaa S. Garg, Mamta Mohamed, Yehia S. Stover, Cordula M. Browning, Michael J. Front Immunol Immunology Multiple myeloma is a life-threatening hematological malignancy, which is rarely curable by conventional therapies. Immunotherapy, using tumor antigen-specific, cytotoxic T-lymphocytes, may represent an alternative or additional treatment for multiple myeloma. In this study, we used hybrid cell lines, generated by fusion of an EBV B-lymphoblastoid cell line (B-LCL) and myeloma cells, to stimulate in vitro peripheral blood lymphocytes (PBLs) from patients with multiple myeloma. We investigated induction of antigen-specific, cytotoxic T-lymphocytes to the well-defined tumor associated antigens (TAAs) hTERT, MUC1, MAGE-C1 and CS1, which have been shown to be expressed in a high proportion of cases of multiple myeloma. HLA-A2-peptide pentamer staining, interferon-γ and perforin ELISpot assays, as well as cytotoxicity assays were used. Following several rounds of in vitro stimulation, the hybrid cell lines induced antigen-specific, cytotoxic T-lymphocytes to four candidate TAAs in PBLs from HLA-A2(+) multiple myeloma patients, using known HLA-A2 restricted peptide epitopes of the TAAs. In contrast, the HLA-A2(+) myeloma cell line U266 failed to induce antigen-specific, cytotoxic T-lymphocytes in vitro. Our data indicate that B-LCL/myeloma hybrid cell lines induce antigen-specific, cytotoxic T-lymphocytes in PBLs isolated from multiple myeloma patients in vitro and may represent a novel strategy for use in adoptive immunotherapy of multiple myeloma. Frontiers Media S.A. 2019-08-02 /pmc/articles/PMC6687956/ /pubmed/31428094 http://dx.doi.org/10.3389/fimmu.2019.01792 Text en Copyright © 2019 Khalaf, Garg, Mohamed, Stover and Browning. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Khalaf, Wafaa S. Garg, Mamta Mohamed, Yehia S. Stover, Cordula M. Browning, Michael J. In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma |
title | In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma |
title_full | In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma |
title_fullStr | In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma |
title_full_unstemmed | In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma |
title_short | In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma |
title_sort | in vitro generation of cytotoxic t cells with potential for adoptive tumor immunotherapy of multiple myeloma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687956/ https://www.ncbi.nlm.nih.gov/pubmed/31428094 http://dx.doi.org/10.3389/fimmu.2019.01792 |
work_keys_str_mv | AT khalafwafaas invitrogenerationofcytotoxictcellswithpotentialforadoptivetumorimmunotherapyofmultiplemyeloma AT gargmamta invitrogenerationofcytotoxictcellswithpotentialforadoptivetumorimmunotherapyofmultiplemyeloma AT mohamedyehias invitrogenerationofcytotoxictcellswithpotentialforadoptivetumorimmunotherapyofmultiplemyeloma AT stovercordulam invitrogenerationofcytotoxictcellswithpotentialforadoptivetumorimmunotherapyofmultiplemyeloma AT browningmichaelj invitrogenerationofcytotoxictcellswithpotentialforadoptivetumorimmunotherapyofmultiplemyeloma |